Dendritic cell-lymphocyte clusters that form spontaneously in rheumatoid arthritis synovial effusions differ from clusters formed in human mixed leukocyte reactions

Synergistic and receptor-mediated targeting of arthritic joints via intra-articular injectable smart hydrogels containing leflunomide-loaded lipid nanocarriers

Intra-articular drug delivery represents a tempting strategy for local treatment of rheumatoid arthritis. Targeting drugs to inflamed joints bypasses systemic-related side effects. Albeit, rapid drug clearance and short joint residence limit intra-articular administration. Herein, injectable smart hydrogels comprising free/nanoencapsulated leflunomide (LEF) were developed. Nanostructured lipid carriers (NLCs), 200-300 nm, were coated with either chondroitin sulfate (CHS), hyaluronic acid (HA), or chitosan (CS) to provide joint targetability. Coated NLCs were incorporated in either hyaluronic/pluronic (HP) or chitosan/β-glycerophosphate (CS/βGP) hydrogels. Optimized systems ensured convenient gelation time (14-100 s), injectability (5-15 s), formulation-dependent mechanical strength, and extended LEF release up to 51 days. In vivo intra-articular injection in induced arthritis rat model revealed that rats treated with HA-coated NLCs showed the fastest recovery. Histopathological examination demonstrated perfect joint healing in case of HA-coated LEF-NLCs in CS/βGP thermogel manifested as minor erosion of subchondral bone, improved intensity of extracellular matrix, cartilage thickness, and chondrocyte number. Both HA- and CHS-coated NLCs reduced TNF-α level 4-5-fold relative to positive control. The feat would be achieved via active targeting to CD44 receptors overexpressed in the articular tissue, limiting chondrocyte apoptosis together with innate synergistic targetability by promoting chondrocyte proliferation and neovascularization, inhibiting the production of pro-inflammatory cytokines, thus enhancing cartilaginous tissue repair.

CD8high+ (CD57+) T cells in patients with rheumatoid arthritis

OBJECTIVE

To investigate the development and T cell receptor (TCR) usage of CD8+, CD57+ T cells in rheumatoid arthritis (RA) patients.

METHODS

Three-color flow cytometry using monoclonal antibodies (MAb) to CD8, CD57 and different TCR V beta gene products.

RESULTS

The proportion of CD8+ T cells expressing CD57 (CD57/CD8) was significantly higher in RA patients compared with age-matched controls. Expanded TCR V beta populations were more frequent, and were found in both RA patient-derived CD8high+ (CD57+) and CD8+, CD57- populations. TCR V beta 5+ and TCR V beta 13+ expansions were present at high frequency (5 of 26 and 7 of 26, respectively). TCR V beta expansions in CD8high+ (CD57+) lymphocytes from RA patients were significantly larger than those in age-matched controls (expansion index 2.38 +/- 0.28, n = 41 and 1.63 +/- 0.09, n = 32, respectively), and were stable over time.

CONCLUSION

RA leads to an increase in the frequency of expanded CD8+ T cell subsets expressing selected TCR, due to expansion of TCR V beta + populations in CD8high+ (CD57+) T cells. Their restricted TCR usage suggests potential specificity for RA antigens and, therefore, a potential role in the pathogenesis of RA.

Cytokine-induced differentiation of cultured nonadherent macrophages

Monocytes were isolated from peripheral blood and cultured in vitro for more than 3 weeks in glass chamber slides. Phenotypically and ultrastructurally these nonadherent macrophages (NAM) appear similar to connective tissue resident macrophages. They constitutively secrete a high amount of IL-1ra and little or no IL-1 alpha or IL-1 beta. When exposed to GM-CSF, IL-2, or IFN-gamma for 24 hr, NAM become adherent and undergo dramatic morphological changes. Cytokines treatment primes NAM for increased LPS-mediated TNF production and these GM-CSF- and LPS-treated NAM are cytotoxic to WEHI 164, a TNF-sensitive target. Morphological changes and TNF production are both inhibited by antimetabolites and a variety of antineoplastic drugs. Although morphology inhibition is reversible under certain circumstances, inhibition of TNF synthesis is irreversible. These findings suggest that cytokines might play a role in differentiation and maturation of long-term cultured monocytes. Furthermore, the effects of antimetabolites and antineoplastic drugs on arresting the differentiation processes may significantly impair antitumor functions of macrophages.

High percentage of CD8+, Leu-7+ cells in rheumatoid arthritis synovial fluid

OBJECTIVE

While analyzing the phenotype of the synovial fluid mononuclear cells (SFMC) clustered about dendritic cells in rheumatoid arthritis (RA) joint effusions, it was noted that most of the clustering cells were CD8+ and coexpressed Leu-7. Therefore, the present study was conducted to investigate the frequency of CD8+, Leu-7+ cells in RA SF:

METHODS

SFMC from 13 patients with RA and from 12 patients with non-RA inflammatory arthritides were examined for CD8 and Leu-7 expression using 2-color immunofluorescence flow cytometry.

RESULTS

RA SFMC had statistically significantly greater percentages of total CD8+ cells, total Leu-7+ cells, and CD8+, Leu-7+ cells, compared with SFMC from the non-RA patients. These RA CD8+, Leu-7+ SFMC had a distinctive electron microscopic appearance compared with CD8+, Leu-7- SFMC. When peripheral blood mononuclear cells (PBMC) from 31 RA patients (including 7 from the SFMC group) were compared with PBMC from 15 normal controls, the percentage of CD8+, Leu-7+ cells was not significantly greater in the RA patients. However, the combination of a modest increase in CD8+, Leu-7+ cells and a decrease in total CD8 cells in RA PBMC altered the composition of the RA CD8 population compared with normal PBMC, such that over 40% of RA peripheral blood CD8 cells coexpressed Leu-7.

CONCLUSION

The increased frequency of CD8+, Leu-7+ cells in RA SFMC may arise from the fact that a high percentage of the CD8+ PBMC in RA patients are also Leu-7+. This altered composition of CD8 cells in RA SF may have a role in the pathogenesis of the disease.

Characterization of the binucleated giant cells generated in the autologous mixed leucocyte reaction from patients with rheumatoid arthritis

Binucleated giant cells several times larger than lymphocytes or monocytes were generated in an autologous mixed leucocyte reaction (AMLR) independent of DNA synthesis in patients with rheumatoid arthritis (RA). The AMLR giant cells with multiple cytoplasmic granules were non-specific esterase-staining positive, phagocytic, non-adherent, HLA-DR+, CD11b+, CD14+, 4F2+, CDW29+, and anti-transferrin receptor positive, but negative for T, B, or NK markers. RA patients aged less than 60 years from more giant cells: 12.6 +/- 13.5% (n = 33) as compared with 0.4 +/- 1.5% in age- and sex-matched normals (n = 38, (P less than 0.001). More giant cells were seen over age 60 in both groups: RA 20.1 +/- 15.5% (n = 5) and healthy controls 3.0 +/- 3.2% (n = 8) (P less than 0.01). Neither disease activity nor treatment appear to influence the result in RA. The giant cells that are probably derived from monocytes in AMLR may explain the formation of the giant cells in rheumatoid granulation tissues.

Dendritic cells in human blood and synovial exudates

Dendritic cells from human blood and synovial exudates are distinct from other leukocytes and are homogeneous by several criteria. Morphologically, their most prominent feature is numerous veils. Phenotypically, dendritic cells lack the surface antigens that identify monocytes, T cells, B cells, and NK cells. Human dendritic cells strongly express class I and class II MHC products, and have a distinct array of integrin and adhesin molecules. In many systems, dendritic cells are potent stimulators of T cell function. In the allogeneic mixed leukocyte reaction, for example, dendritic cells are 30-100 times more efficient than other cells in presenting transplantation antigens, for the induction of DNA synthesis, cytokine release, and generation of cytotoxic T cells. In addition, dendritic cells can induce the long-term clonal growth of T lymphocytes. Although dendritic cells are a minor subpopulation in human blood, new isolation protocols are available that permit efficient isolation and enrichment to > 90%.

Differences in responses of normal and rheumatoid arthritis peripheral blood T cells to synovial fluid and peripheral blood dendritic cells in allogeneic mixed leukocyte reactions

We examined the response of normal T cells to dendritic cells isolated from the synovial fluid (SF) of patients with either rheumatoid arthritis (RA) or seronegative spondylarthropathies (rheumatoid variants) and to dendritic cells from normal and RA peripheral blood (PB) in the allogeneic mixed leukocyte reaction. Despite the differences in the response kinetics, the stimulatory capacity of SF dendritic cells was similar to that of PB dendritic cells in a 7-day mixed leukocyte reaction. We also tested the responsiveness of normal and RA PB T cells to various allogeneic dendritic cells and found that RA PB T cells responded poorly to both rheumatoid variant SF dendritic cells and normal PB dendritic cells. However, when dendritic cells from RA SF were used as stimulators, the response of RA PB T cells was significantly greater than that of normal PB T cells (P less than 0.02). This difference in response was explained in part by a proliferation of the CD8 T cell subset. There was also a shift of low-intensity CD4+, CDw29+ cells to high-intensity CD4+, CDw29+ cells seen in RA PB T cells but not in normal PB T cells, by fluorescence-activated cell sorter analysis.

Cytokines in chronic inflammatory arthritis. III. Rheumatoid arthritis monocytes are not unusually sensitive to gamma-interferon, but have defective gamma-interferon-mediated HLA-DQ and HLA-DR induction

Macrophages present in the synovium and synovial fluid of patients with rheumatoid arthritis (RA) express large amounts of HLA-DR molecules on their surface, despite low levels of gamma-interferon (gamma-IFN) in the joint. To determine whether this apparent paradox is the result of increased sensitivity to gamma-IFN in RA, we compared concentrations of gamma-IFN that induced HLA-DR and DQ on peripheral blood monocytes of RA patients and normal donors, using fluorescence-activated cell sorter analysis. Among normal donors, highly variable sensitivity to gamma-IFN was observed. Higher amounts of gamma-IFN were required to induce class II major histocompatibility complex molecules on RA monocytes versus normal monocytes. The maximum amount of HLA-DR that could be induced on RA and normal monocytes was similar; however, peak levels of HLA-DQ were significantly less in RA. Monocytes from patients with other forms of chronic inflammatory arthritis had intermediate HLA-DQ expression after gamma-IFN treatment. These data suggest that an increased sensitivity to gamma-IFN in RA does not account for the high level of HLA-DR expression in the joint. Also, a defect in HLA-DQ and HLA-DR induction by gamma-IFN was observed.

A functional study of purified CD4+ and CD8+ cells isolated from synovial fluid of patients with rheumatoid arthritis and other arthritides

The purpose of this investigation was to study purified synovial fluid (SF) CD4+ and CD8+ cells from patients with rheumatoid arthritis (RA) and other inflammatory joint diseases (non-RA) with respect to the proliferative response to mitogens and recombinant interleukin 2 (rIL-2). Highly purified cell subsets were isolated by an immunomagnetic technique, and spontaneous proliferation as well as proliferative reSponses to rIL-2 and a combination of phytohaemagglutinin (PHA) and phorbol myristate acetate (PMA) (to substitute for accessory cells) were measured. Some patients had SF CD4+ and/or CD8+ cells with moderately increased spontaneous proliferation, but only the CD4+ cells of the two patient groups differed significantly from the peripheral blood (PB) T-cell subsets of healthy individuals who served as controls. The response to rIL-2 was variable but generally low, although about 50% of the CD4+ and 20% of the SF CD8+ cells of both patient groups expressed the Tac antigen. The response to PHA/PMA was significantly lower for RA SF CD4+ cells than for non-RA SF CD4+ cells, which again was lower than for normal PB CD4+ cells. SF CD8+ response to PMA/PHA by both groups of patients was somewhat decreased, but not significantly lower than in the controls. Thus, the CD4+ cells seemed functionally more deviant than the CD8+ cells in both patient groups, but the abnormality was most pronounced in the RA group. The results demonstrate that the previously reported diminished response to mitogens by SF mononuclear cells is present even when SF CD4+ cells are cultured alone. This indicates that these T cells have a reduced response, probably because of prior activation.

Dendritic cells in health and disease

Cells with a dendritic morphology that are rich in surface class II histocompatibility antigens (Ia antigens) but lacking in other lymphocytes or monocyte markers constitute a small (less than 1%) proportion of circulating mononuclear cells, but in inflammatory joint effusions they comprise up to 7% of the mononuclear population. Their role as accessory cells in normal autologous and allogenic mixed leukocyte reactions is reviewed and the possible contribution of dendritic cells to intra-articular immunologic processes is considered.